

5th HEPATITIS C
TECHNICAL ADVISORY
GROUP
TAG Meeting

**HBV/HCV COINFECTION AMONG
PATIENTS ENROLLED IN HEPATITIS C
ELIMINATION PROGRAM**

Maia Butsashvili, MD, MS, PhD
Health Research Union/Clinic NeoLab

Objectives of the study

- To study the prevalence of hepatitis B surface antigen (HBsAg) among patients enrolled in the HCV elimination program
- To study exposure status (antiHBc or antiHBs) among these patients
- To compare clinical data among HBV coinfecting and HCV mono-infected patients
- To evaluate HCV treatment outcome among HBV/HCV coinfecting individuals


Methods

- Data were extracted from elimination program database
- HBV exposure was estimated by the presence of antiHBc or antiHBs

Note: During the two years since the beginning of the program antiHBs was done and later changed to antiHBc

- Statistical analysis:
 - Unadjusted and adjusted prevalence ratios were calculated to study association between the HCV mono and HBV co-infection status and other demographic/clinical data

Prevalence and exposure to HBV infection




General population:

2015 sero-survey


Antibodies – 25.5%

HBsAg – 2.9%


Association of demographic characteristics with HBV status: Age




Association of demographic characteristics with HBV status: *Gender*




Liver fibrosis level (elastography)




Liver fibrosis level (FIB4 score)




History of injection drug use



Elevated ALT



HCV treatment outcome



Major findings

- HBV co-infection does not change HCV treatment outcome
- Younger patients have higher risk of active HBV infection
- Males have higher exposure as well as active infection rate
- Liver fibrosis level is not different among mono- and co-infected patients
- PWID – independent risk factors of active HBV infection
- Difference in ALT level is increasing at later stages of HCV antiviral treatment

Challenges

- HBV DNA testing is not done among HBsAg positive individuals enrolled in HCV treatment
- HBV antiviral treatment is not available for HBV infected patients receiving HCV treatment
- PWID are not vaccinated against hepatitis B

Note: HBV vaccination is offered to patients enrolled in elimination program

Acknowledgements

- Shaun Shadaker
- Lia Gvinjilia
- Tatia Kuchuloria



Thank you